Trial reportNature medicine2021
Early treatment of COVID-19 with anakinra guided by soluble urokinase plasminogen receptor plasma levels: a double-blind, randomized controlled phase 3 trial.
Erratum issuedOpen access · hybridAbstract readClinical Trial, Phase IIIRandomized Controlled Trial
In one paragraph
Trial report in Nature medicine, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 351 papers, 12 of them syntheses that pooled it.
0numbers the graph read from it
0cells of the map it votes in
351citing papers in PubMed, 12 pooled it
29.8field-weighted citation impact, top 1% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
351 citing papers in PubMed, 12 syntheses or guidelines pooled it, 528 citations in OpenAlex.
- Guideline
- A consensus blood transcriptomic framework for sepsis.Nature medicine · 2025Guideline
- A consensus immune dysregulation framework for sepsis and critical illnesses.Nature medicine · 2025Guideline
- Predictive enrichment using biomarkers in studies of critically-ill patients with sepsis: a systematic review.Critical care (London, England) · 2025Pooled it
- Effectiveness of pharmacological treatments for COVID-19 due to SARS-CoV-2: a systematic literature review.Frontiers in pharmacology · 2025Pooled it
- Clinical efficacy and safety of interleukin-1 blockade in the treatment of patients with COVID-19: a systematic review and meta-analysis of randomized controlled trials.Annals of medicine · 2023Pooled it
- Assessment of the available therapeutic approaches for severe COVID-19: a meta-analysis of randomized controlled trials.Scientific reports · 2023Pooled it
- Interleukin-6 blocking agents for treating COVID-19: a living systematic review.The Cochrane database of systematic reviews · 2023Pooled it
- AGIHO guideline on evidence-based management of COVID-19 in cancer patients: 2022 update on vaccination, pharmacological prophylaxis and therapy in light of the omicron variants.European journal of cancer (Oxford, England : 1990) · 2023Guideline
- Anakinra for the treatment of COVID-19 patients: a systematic review and meta-analysis.European journal of medical research · 2023Pooled it
- Comparison of Preprint Postings of Randomized Clinical Trials on COVID-19 and Corresponding Published Journal Articles: A Systematic Review.JAMA network open · 2023Pooled it
- Effect of anti-inflammatory drugs on the storm of inflammatory factors in respiratory tract infection caused by SARS-CoV-2: an updated meta-analysis.Frontiers in public health · 2023Pooled it
- Molecular pathways driving clarithromycin benefit in community-acquired pneumonia: analysis of the ACCESS randomised trial.EBioMedicine · 2026Trial
- Soluble urokinase plasminogen activator receptor and outcomes in HFpEF: A TOPCAT ancillary study.ESC heart failure · 2025Trial
- Trial
- The Value of Soluble Urokinase Plasminogen Activator Receptor (suPAR) as Predictive Tool in Hospitalised Patients With Community-Acquired Pneumonia (CAP).The clinical respiratory journal · 2025Trial
- Heterogeneity of treatment effect of vilobelimab in COVID-19: a secondary analysis of a randomised controlled trial.Critical care (London, England) · 2024Trial
- Viral and Host Factors Are Associated With Mortality in Hospitalized Patients With COVID-19.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2024Trial
- Transitions of blood immune endotypes and improved outcome by anakinra in COVID-19 pneumonia: an analysis of the SAVE-MORE randomized controlled trial.Critical care (London, England) · 2024Trial
- Immunomodulatory and clinical effects of receptor-interacting protein kinase 1 (RIPK1) inhibitor eclitasertib (SAR443122) in patients with severe COVID-19: a phase 1b, randomized, double-blinded, placebo-controlled study.Respiratory research · 2024Trial
291 more citing papers are in PubMed but not listed here.
Corrections and comments
- Commented on by
- Erratum issued
Authors and funding
64 authors at 20 institutions in 5 countries.
Evdoxia Kyriazopoulou4th Department of Internal Medicine, National and Kapodistrian University of Athens, Medical School, Athens, Greece.ORCID http://orcid.org/0000-0002-9585-517X
Garyfallia Poulakou3rd Department of Internal Medicine, National and Kapodistrian University of Athens, Medical School, Athens, Greece.
Haralampos Milionis1st Department of Internal Medicine, University of Ioannina, Medical School, Ioannina, Greece.
Simeon Metallidis1st Department of Internal Medicine, Aristotle University of Thessaloniki, Medical School, Thessaloniki, Greece.
Georgios Adamis1st Department of Internal Medicine, G. Gennimatas General Hospital of Athens, Athens, Greece.
Konstantinos Tsiakos2nd Department of Pulmonary Medicine, Sotiria General Hospital of Chest Diseases, Athens, Greece.ORCID http://orcid.org/0000-0002-9167-905X
Archontoula FragkouDepartment of Internal Medicine, Elpis General Hospital, Athens, Greece.
Aggeliki Rapti2nd Department of Pulmonary Medicine, Sotiria General Hospital of Chest Diseases, Athens, Greece.
Christina Damoulari4th Department of Internal Medicine, National and Kapodistrian University of Athens, Medical School, Athens, Greece.
Massimo FantoniDipartimento Scienze di Laboratorio e Infettivologiche - Fondazione Policlinico Gemelli IRCCS, Roma, Italy.ORCID http://orcid.org/0000-0001-6913-8460
Ioannis Kalomenidis1st Department of Critical Care and Pulmonary Medicine, Medical School, National and Kapodistrian University of Athens, Evangelismos General Hospital, Athens, Greece.ORCID http://orcid.org/0000-0001-9729-3492
Georgios Chrysos2nd Department of Internal Medicine, Tzaneio General Hospital of Piraeus, Athens, Greece.
Andrea AnghebenDepartment of Infectious Tropical Diseases and Microbiology, IRCSS Sacro Cuore Hospital, Negrar, Verona, Italy.ORCID http://orcid.org/0000-0003-4545-8034
Ilias Kainis10th Department of Pulmonary Medicine, Sotiria General Hospital of Chest Diseases of Athens, Athens, Greece.
Zoi Alexiou2nd Department of Internal Medicine, Thriasio General Hospital of Eleusis, Athens, Greece.
Francesco CastelliSpedali Civili, Brescia ASST Spedali Civili Hospital, University of Brescia, Brescia, Italy.
Francesco Saverio SerinoDepartment of Internal Medicine, Hospital of Jesolo, Jesolo, Italy.
Maria Tsilika4th Department of Internal Medicine, National and Kapodistrian University of Athens, Medical School, Athens, Greece.
Petros Bakakos1st Department of Chest Medicine, National and Kapodistrian University of Athens, Medical School, Athens, Greece.
Emanuele NicastriDepartment of Internal Medicine, Spallanzani Institute of Rome, Rome, Italy.
Vassiliki Tzavara1st Department of Internal Medicine, Korgialeneion-Benakeion General Hospital, Athens, Greece.
Evangelos KostisDepartment of Therapeutics, National and Kapodistrian University of Athens, Medical School, Athens, Greece.
Lorenzo DagnaUnit of Immunology, Rheumatology, Allergy and Rare Diseases (UnIRAR), IRCCS Ospedale San Raffaele & Vita-Salute San Raffaele University, Milan, Italy.ORCID http://orcid.org/0000-0002-7428-315X
Panagiotis Koufargyris4th Department of Internal Medicine, National and Kapodistrian University of Athens, Medical School, Athens, Greece.ORCID http://orcid.org/0000-0001-7800-3306
Katerina Dimakou5th Department of Pulmonary Medicine, Sotiria General Hospital of Chest Diseases, Athens, Greece.
Spyridon SavvanisDepartment of Internal Medicine, Elpis General Hospital, Athens, Greece.
Glykeria Tzatzagou1st Department of Internal Medicine, Papageorgiou General Hospital of Thessaloniki, Thessaloniki, Greece.
Maria Chini3rd Department of Internal Medicine and Infectious Diseases Unit, Korgialeneion-Benakeion General Hospital, Athens, Greece.
Giulio CavalliUnit of Immunology, Rheumatology, Allergy and Rare Diseases (UnIRAR), IRCCS Ospedale San Raffaele & Vita-Salute San Raffaele University, Milan, Italy.
Matteo BassettiInfectious Diseases Clinic, Ospedale Policlinico San Martino IRCCS and Department of Health Sciences, University of Genova, Genova, Italy.
Konstantina Katrini4th Department of Internal Medicine, National and Kapodistrian University of Athens, Medical School, Athens, Greece.
Vasileios Kotsis3rd Department of Internal Medicine, Aristotle University of Thessaloniki, Medical School, Thessaloniki, Greece.
George Tsoukalas4th Department of Pulmonary Medicine, Sotiria General Hospital of Chest Diseases, Athens, Greece.
Carlo SelmiDepartment of Biomedical Sciences, Humanitas University, Milan, Italy & IRCCS Humanitas Research Hospital, Milan, Italy.
Ioannis Bliziotis1st Department of Internal Medicine, Asklepieio General Hospital of Voula, Athens, Greece.
Michael Samarkos1st Department of Internal Medicine, National and Kapodistrian University of Athens, Medical School, Athens, Greece.ORCID http://orcid.org/0000-0001-9630-9712
Michael Doumas2nd Department of Propedeutic Medicine, Aristotle University of Thessaloniki, Medical School, Thessaloniki, Greece.
Sofia Ktena4th Department of Internal Medicine, National and Kapodistrian University of Athens, Medical School, Athens, Greece.
Aikaterini Masgala2nd Department of Internal Medicine, Konstantopouleio General Hospital, Athens, Greece.
Ilias PapanikolaouDepartment of Pulmonary Medicine, General Hospital of Kerkyra, Corfu, Greece.ORCID http://orcid.org/0000-0003-1391-2925
Maria Kosmidou1st Department of Internal Medicine, University of Ioannina, Medical School, Ioannina, Greece.ORCID http://orcid.org/0000-0002-8618-9435
Dimitra-Melia Myrodia3rd Department of Internal Medicine, National and Kapodistrian University of Athens, Medical School, Athens, Greece.
Aikaterini ArgyrakiDepartment of Internal Medicine, Sotiria General Hospital of Chest Diseases, Athens, Greece.
Chiara Simona CardellinoDepartment of Infectious Tropical Diseases and Microbiology, IRCSS Sacro Cuore Hospital, Negrar, Verona, Italy.
Katerina KoliakouHellenic Institute for the Study of Sepsis, Athens, Greece.
Eleni-Ioanna KatsigianniHellenic Institute for the Study of Sepsis, Athens, Greece.
Vassiliki Rapti3rd Department of Internal Medicine, National and Kapodistrian University of Athens, Medical School, Athens, Greece.
Efthymia Giannitsioti2nd Department of Internal Medicine, Tzaneio General Hospital of Piraeus, Athens, Greece.
Antonella CingolaniDipartimento Scienze di Laboratorio e Infettivologiche - Fondazione Policlinico Gemelli IRCCS, Roma, Italy.
Styliani MichaHellenic Institute for the Study of Sepsis, Athens, Greece.
Karolina AkinosoglouDepartment of Internal Medicine, University of Patras, Rion, Greece.
Orestis Liatsis-DouvitsasHellenic Institute for the Study of Sepsis, Athens, Greece.ORCID http://orcid.org/0000-0002-0927-920X
Styliani Symbardi1st Department of Internal Medicine, Thriasio General Hospital of Eleusis, Athens, Greece.
Nikolaos GatselisDepartment of Medicine and Research Laboratory of Internal Medicine, National Expertise Center of Greece in Autoimmune Liver Diseases, General University Hospital of Larissa, Larissa, Greece.
Maria Mouktaroudi4th Department of Internal Medicine, National and Kapodistrian University of Athens, Medical School, Athens, Greece.
Giuseppe IppolitoDepartment of Internal Medicine, Spallanzani Institute of Rome, Rome, Italy.ORCID http://orcid.org/0000-0002-1076-2979
Eleni FlorouHellenic Institute for the Study of Sepsis, Athens, Greece.ORCID http://orcid.org/0000-0002-1201-099X
Antigone Kotsaki4th Department of Internal Medicine, National and Kapodistrian University of Athens, Medical School, Athens, Greece.
Mihai G NeteaDepartment of Internal Medicine and Center for Infectious Diseases, Radboud University, Nijmegen, The Netherlands.ORCID http://orcid.org/0000-0003-2421-6052
Jesper Eugen-OlsenDepartment of Clinical Research, Copenhagen University Hospital, Amager and Hvidovre, Denmark.ORCID http://orcid.org/0000-0002-4630-4275
Miltiades KyprianouHellenic Institute for the Study of Sepsis, Athens, Greece.ORCID http://orcid.org/0000-0003-1260-1789
Periklis Panagopoulos2nd Department of Internal Medicine, Democritus University of Thrace, Medical School, Alexandroupolis, Greece.
George N DalekosDepartment of Medicine and Research Laboratory of Internal Medicine, National Expertise Center of Greece in Autoimmune Liver Diseases, General University Hospital of Larissa, Larissa, Greece.
Evangelos J Giamarellos-Bourboulis4th Department of Internal Medicine, National and Kapodistrian University of Athens, Medical School, Athens, Greece. egiamarel@med.uoa.gr.ORCID http://orcid.org/0000-0003-4713-3911
National and Kapodistrian University of Athens · GRSotiria General Hospital · GRAristotle University of Thessaloniki · GRAgostino Gemelli University Polyclinic · ITGeneral Hospital of Athens Elpis · GRIstituto Nazionale per le Malattie Infettive Lazzaro Spallanzani · ITOspedale Sacro Cuore Don Calabria · ITThriasio General Hospital of Elefsina · GRTzaneion General Hospital · GRUniversity Hospital of Larissa · GRUniversity of Ioannina · GRVita-Salute San Raffaele University · ITAgia Olga Hospital · GRAmager Hospital · DKAzienda Socio Sanitaria Territoriale degli Spedali Civili di Brescia · ITDemocritus University of Thrace · GRGeneral Hospital Asklepieio Voulas · GRGeneral Hospital of Athens G. Genimatas · GRHumanitas University · ITOspedale Policlinico San Martino · IT
Funding
No grant is acknowledged in the PubMed record.
Abstract
Early increase of soluble urokinase plasminogen activator receptor (suPAR) serum levels is indicative of increased risk of progression of coronavirus disease 2019 (COVID-19) to respiratory failure. The SAVE-MORE double-blind, randomized controlled trial evaluated the efficacy and safety of anakinra, an IL-1α/β inhibitor, in 594 patients with COVID-19 at risk of progressing to respiratory failure as identified by plasma suPAR ≥6 ng ml
Indexed as
COVID-19 Drug TreatmentAgedCOVID-19Double-Blind MethodFemaleHumansInterleukin 1 Receptor Antagonist ProteinMaleMiddle AgedPlacebosReceptors, Urokinase Plasminogen ActivatorSARS-CoV-2Interleukin 1 Receptor Antagonist ProteinPlacebosReceptors, Urokinase Plasminogen Activator
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.